Drilldown: Medicines
Medicines > routes:
Oral 
& duration :
12-24 hours or
2-4 hours; headache recurrence rate ~20-30% within 24 hours
& duration :
12-24 hours or
2-4 hours; headache recurrence rate ~20-30% within 24 hours Use the filters below to narrow your results.
generic:
brand:
Allegra, Allegra Allergy 24 Hour, Mucinex Allergy (combo) — all now OTC in US (1) ·
Celebrex (oral capsules), Elyxyb (oral solution, for acute migraine) (1) ·
Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) (1) ·
Omnicef (discontinued in US under brand); mostly generic (1) ·
Vasotec, Vasotec IV, Epaned (1)
classes:
selective COX-2)]] (1) ·
[[:Category:ACE_inhibitors|ACE inhibitor]] (1) ·
[[:Category:Analgesics|Analgesic]] (2) ·
[[:Category:Antihistamines|Antihistamine]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Antimigraine medicines|Antimigraine medicine]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (1) ·
[[:Category:Cephalosporins|Cephalosporin (third-generation)]] (1) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (1) ·
[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID (1) ·
[[:Category:Triptans|Triptan (5-HT1B/1D agonist)]] (1)
mechanism:
uses:
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) ·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (1) ·
'"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"' (1) ·
'"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"' (1) ·
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"' (1)
starting dose:
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d (1) ·
5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) ·
60 mg PO BID or 180 mg PO once daily (1) ·
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1) ·
Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours (1)
preparations:
2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) ·
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC (1) ·
300 mg capsules; 125, 250 mg/5 mL suspension (1) ·
Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL (1) ·
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1)
fda max:
routes: (Click arrow to add another value)
onset:
duration: (Click arrow to add another value)
halflife:
bioavailability:
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"' (1) ·
~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' (1) ·
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1) ·
~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1) ·
~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1)
pregnancy:
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (1) ·
Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.